Bright Biotech Limited 12253910 false 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is bitech engineering. Digita Accounts Production Advanced 6.30.9574.0 true 12253910 2025-01-01 2025-12-31 12253910 2025-12-31 12253910 core:RetainedEarningsAccumulatedLosses 2025-12-31 12253910 core:ShareCapital 2025-12-31 12253910 core:SharePremium 2025-12-31 12253910 core:CurrentFinancialInstruments 2025-12-31 12253910 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 12253910 core:FurnitureFittings 2025-12-31 12253910 core:OfficeEquipment 2025-12-31 12253910 core:OtherPropertyPlantEquipment 2025-12-31 12253910 bus:SmallEntities 2025-01-01 2025-12-31 12253910 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 12253910 bus:FilletedAccounts 2025-01-01 2025-12-31 12253910 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 12253910 bus:RegisteredOffice 2025-01-01 2025-12-31 12253910 bus:Director1 2025-01-01 2025-12-31 12253910 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 12253910 core:ComputerEquipment 2025-01-01 2025-12-31 12253910 core:FurnitureFittings 2025-01-01 2025-12-31 12253910 core:OfficeEquipment 2025-01-01 2025-12-31 12253910 core:OtherPropertyPlantEquipment 2025-01-01 2025-12-31 12253910 core:PlantMachinery 2025-01-01 2025-12-31 12253910 countries:EnglandWales 2025-01-01 2025-12-31 12253910 2024-12-31 12253910 core:FurnitureFittings 2024-12-31 12253910 core:OfficeEquipment 2024-12-31 12253910 core:OtherPropertyPlantEquipment 2024-12-31 12253910 2024-01-01 2024-12-31 12253910 2024-12-31 12253910 core:RetainedEarningsAccumulatedLosses 2024-12-31 12253910 core:ShareCapital 2024-12-31 12253910 core:SharePremium 2024-12-31 12253910 core:CurrentFinancialInstruments 2024-12-31 12253910 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 12253910 core:FurnitureFittings 2024-12-31 12253910 core:OfficeEquipment 2024-12-31 12253910 core:OtherPropertyPlantEquipment 2024-12-31 iso4217:GBP xbrli:pure

Registration number: 12253910

Bright Biotech Limited
Unaudited Financial Statements
for the Year Ended 31 December 2025

Bright Biotech Limited

Contents

Balance Sheet | 1
Notes to the Unaudited Financial Statements | 2 to 4

Bright Biotech Limited

(Registration number: 12253910)
Balance Sheet as at 31 December 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 4 | 182,696 | 221,199
Current assets |  |  |
Debtors | 5 | 9,574 | 14,274
Cash at bank and in hand |  | 442,124 | 667,115
|  | 451,698 | 681,389
Creditors: Amounts falling due within one year | 6 | (21,778) | (21,437)
Net current assets |  | 429,920 | 659,952
Net assets |  | 612,616 | 881,151
Capital and reserves |  |  |
Called up share capital |  | 1 | 1
Share premium reserve |  | 2,653,377 | 2,249,325
Retained earnings |  | (2,040,762) | (1,368,175)
Shareholders' funds |  | 612,616 | 881,151

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 23 July 2026 and signed on its behalf by:

......................................... Dr Mohammad El Hajj Director

Bright Biotech Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Rutherford House Unit 16 Pencroft Way
Manchester Science Park
Manchester
M15 6SZ
England

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Judgements

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where revision affects only that period, or in the period of revision and future periods where the revision affects both current and future periods.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Bright Biotech Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Fixtures & fittings | 15% Reducing balance
Computer equipment | 20% Reducing balance
Plant & machinery | 20% Reducing balance

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 10 (2024 - 8).

Bright Biotech Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

4 | Tangible assets

| Fixtures and fittings £ | Computer equipment £ | Plant & machinery £ | Total £
Cost or valuation
At 1 January 2025 | 42,801 | 6,186 | 311,278 | 360,265
Additions | - | - | 4,029 | 4,029
At 31 December 2025 | 42,801 | 6,186 | 315,307 | 364,294
Depreciation
At 1 January 2025 | 13,187 | 1,535 | 124,344 | 139,066
Charge for the year | 4,442 | 636 | 37,454 | 42,532
At 31 December 2025 | 17,629 | 2,171 | 161,798 | 181,598
Carrying amount
At 31 December 2025 | 25,172 | 4,015 | 153,509 | 182,696
At 31 December 2024 | 29,614 | 4,651 | 186,934 | 221,199

5 | Debtors

Current | 2025 £ | 2024 £
Prepayments | 1,762 | 1,352
Other debtors | 7,812 | 12,922
| 9,574 | 14,274

6 | Creditors

Creditors: amounts falling due within one year

| 2025 £ | 2024 £
Due within one year |  |
Trade creditors | 6,353 | 6,261
Taxation and social security | 10,120 | 10,910
Accruals and deferred income | 3,359 | 1,450
Other creditors | 1,946 | 2,816
| 21,778 | 21,437